Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie 
Welcome,         Profile    Billing    Logout  
 9 Diseases   32 Trials   32 Trials   762 News 


«12345678910»
  • ||||||||||  Linzess (linaclotide) / Allergan, Astellas, Ironwood Pharma
    [VIRTUAL] MOBILIZATION OF ENDOGENOUS HEMATOPOIETIC SYSTEM FOR TREATMENT OF ALZHEIMER’S DISEASE (Hall E) -  Jan 6, 2020 - Abstract #AATADPD2020AAT_ADPD_281;    
    The combination of AMD31100 -lactate have a beneficial effect by improving cognitive deficit, reducing Tau and APP pathologies and lead to shift in microglia to anti-inflammatory status Conclusions The combination of AMD3100 and lactate down regulate CXCR4/CXCL12 interaction, shift the neuroinflammation from a neurotoxic profile to a neuroprotective one. This shift attenuated pathological features of AD and ameliorate the cognitive functions .
  • ||||||||||  Linzess (linaclotide) / Allergan, Astellas, Ironwood Pharma
    Journal:  Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction. (Pubmed Central) -  Dec 21, 2019   
    Linaclotide itself does not inhibit bladder afferents, rather normalization of bladder function by daily linaclotide treatment occurs via indirect inhibition of bladder afferents via reduced nociceptive signaling from the colon. These data support the concepts that cross-organ sensitization underlies the development and maintenance of visceral comorbidities, while pharmaceutical treatments that inhibit colonic afferents may also improve urological symptoms through common sensory pathways.
  • ||||||||||  Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
    Enrollment open:  Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C (clinicaltrials.gov) -  Nov 28, 2019   
    P3,  N=120, Recruiting, 
    These data support the concepts that cross-organ sensitization underlies the development and maintenance of visceral comorbidities, while pharmaceutical treatments that inhibit colonic afferents may also improve urological symptoms through common sensory pathways. Not yet recruiting --> Recruiting
  • ||||||||||  Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
    Enrollment open:  Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer (clinicaltrials.gov) -  Nov 10, 2019   
    P2,  N=230, Recruiting, 
    Specific high-quality trials are needed to enrich the evidence. Not yet recruiting --> Recruiting
  • ||||||||||  Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine
    Review, Journal:  Update on Pharmacotherapy for Irritable Bowel Syndrome. (Pubmed Central) -  Oct 29, 2019   
    Tenapanor, a sodium/hydrogen exchanger 3 inhibitor, appears to be a promising treatment option in the pipeline...There are no established pharmacologic agents for IBS with a mixed bowel pattern. There is a promising pipeline for additional novel therapies for IBS.
  • ||||||||||  Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
    Trial completion date, Trial primary completion date:  Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation (clinicaltrials.gov) -  Oct 28, 2019   
    P2,  N=30, Recruiting, 
    There is a promising pipeline for additional novel therapies for IBS. Trial completion date: Jun 2022 --> Feb 2023 | Trial primary completion date: Jun 2022 --> Feb 2023
  • ||||||||||  Linzess (linaclotide) / Allergan, Astellas, Ironwood
    A Guanylate Cyclase C Agonist Linaclotide Reduces Trimethylamine N-Oxide in an Adenine-Induced CKD Model (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_3776;    
    By metagenome analysis, microbial order Clostridiales may have been responsible for the change in TMAO. Conclusion Linaclotide reduced TMAO and uremic toxin levelsand be a potent tool for the cardio-renal syndrome by modification of the “gut-cardiorenal axis” gut-cardiorenal axis Funding Government Support - Non-U.S.
  • ||||||||||  Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
    Trial completion:  Internal Limiting Membrane Peeling-reposition to Treat Idiopathic Macular Holes (clinicaltrials.gov) -  Oct 10, 2019   
    P=N/A,  N=29, Completed, 
    Conclusion Linaclotide reduced TMAO and uremic toxin levelsand be a potent tool for the cardio-renal syndrome by modification of the “gut-cardiorenal axis” gut-cardiorenal axis Funding Government Support - Non-U.S. Active, not recruiting --> Completed
  • ||||||||||  Linzess (linaclotide) / Allergan, Astellas, Ironwood, Resolor (prucalopride) / J&J, Takeda, relamorelin (RM-131) / Allergan
    Journal:  Gastrointestinal involvement in systemic sclerosis: diagnosis and management. (Pubmed Central) -  Oct 8, 2019   
    Combination therapies are also under study. Electroacupuncture, dietary intervention (e.g. medical nutrition therapy, low FODmap diet), and medical cannibus may also play a role in alleviating patient symptoms; however, more data are needed to define the role of these interventions in SSc.
  • ||||||||||  Linzess (linaclotide) / Allergan, Astellas, Ironwood
    Linaclotide for the Treatment of Gastrointestinal Symptoms in Systemic Sclerosis (Hall B5) -  Oct 7, 2019 - Abstract #ACRARHP2019ACR_2706;    
    Linaclotide is a well-tolerated and efficacious prosecretory agent that can be used to manage refractory constipation in who have failed management with over the counter laxatives and/or stool softeners. We find that low-dose treatments with linaclotide are an effective option with a lower side effect profile than high-dose treatment regimens, though high doses are required for optimal symptom control in some patients.
  • ||||||||||  Linzess (linaclotide) / Allergan, Astellas, Ironwood, Resolor (prucalopride) / J&J, Takeda, Amitiza (lubiprostone) / Takeda, Mallinckrodt
    Review, Journal, HEOR:  Cost Effectiveness of Treatments for Chronic Constipation: A Systematic Review. (Pubmed Central) -  Sep 26, 2019   
    Further analysis is needed comparing all available treatments for patients who have not responded to laxatives. Overall, results from economic evaluations appear to align with stepwise practice guidelines.
  • ||||||||||  Gattex (teduglutide) / Takeda
    Teduglutide Therapy for a Patient With Chronic Intestinal Failure Following Multi-Visceral Transplantation (Exhibit Halls 3 and 4 (Street Level)) -  Aug 8, 2019 - Abstract #ACG2019ACG_2210;    
    Loperamide and Diphenoxylate were also trialed...She was placed on Linaclotide in addition to Teduglutide with the need to maximize TPN requirements...Research is ongoing to discover pharmacologic treatment options that significantly decrease the necessity of TPN and IVF. HGH and GLP-2 agonists are options at this time, however remain in question if they are effective long term.
  • ||||||||||  Linzess (linaclotide) / Allergan, Astellas, Ironwood
    Linaclotide Safety and Efficacy in Children Aged 6 to 17 Years With Functional Constipation (Exhibit Halls 3 and 4 (Street Level)) -  Aug 8, 2019 - Abstract #ACG2019ACG_2154;    
    For the primary endpoint, or the secondary efficacy endpoints, none of the LIN doses (A, B, C) led to a clear improvement over PBO (p ≥ 0.1502) in the ITT population. A trend toward improved efficacy at the high LIN dose vs.
  • ||||||||||  Linzess (linaclotide) / Allergan, Astellas, Ironwood, Trulance (plecanatide) / Synergy Pharmaceuticals Inc., Amitiza (lubiprostone) / Takeda, Mallinckrodt
    The Fragility Index of the Randomized Trials for Irritable Bowel Syndrome With Constipation (Exhibit Halls 3 and 4 (Street Level)) -  Aug 8, 2019 - Abstract #ACG2019ACG_812;    
    studying lubiprostone since the study itself reported a nonsignificant outcome, as well as Novick at al. studying tegaserod (Table 1).
  • ||||||||||  Resolor (prucalopride) / J&J, Takeda
    Journal:  Prucalopride (Motegrity) for chronic idiopathic constipation. (Pubmed Central) -  Aug 6, 2019   
    Our findings suggest a novel treatment paradigm for GC-C agonism in IBS-C and BPS mediated through visceral organ crosstalk, a mechanism not previously linked to linaclotide. No abstract available
  • ||||||||||  Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine
    Review, Journal:  New treatments and therapeutic targets for IBS and other functional bowel disorders. (Pubmed Central) -  Jul 17, 2019   
    The current development of new treatment alternatives is focusing on different aspects of the complex pathophysiology of IBS and other FBDs: gut microenvironment (via diet and modulation of gut microbiota), enterohepatic circulation of bile acids, gastrointestinal secretion, motility and sensation, gut-brain interactions, gut barrier function and the immune system within the gastrointestinal tract. Studies also suggest that personalized treatment of IBS and other FBDs is possible using various diagnostic markers.
  • ||||||||||  Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
    Trial termination:  Efficacy of Linaclotide to Senna for CIC (clinicaltrials.gov) -  Jul 2, 2019   
    P=N/A,  N=9, Terminated, 
    Patients with IBS may benefit from a multipronged, individualized approach to treatment, including dietary modifications, psychological and pharmacological therapies. Completed --> Terminated; Not sufficient recruitment
  • ||||||||||  Resolor (prucalopride) / J&J, Takeda
    Clinical, Review, Journal:  Clinical Efficacy and Safety Profile of Prucalopride in Chronic Idiopathic Constipation. (Pubmed Central) -  Jun 21, 2019   
    The most frequent adverse events were headaches and problems related to the gastrointestinal tract. Caution should be taken when using prucalopride in patients with impaired liver and renal function. In Canada, prucalopride has been approved for treatment of female patients with chronic idiopathic constipation who have failed therapy with at least two laxatives from different classes over a six-month period.
  • ||||||||||  Linzess (linaclotide) / Allergan, Astellas, Ironwood
    Journal:  Long-term treatment with linaclotide of intestinal pseudo-obstruction secondary to Ehlers-Danlos syndrome. (Pubmed Central) -  Jun 15, 2019   
    Caution should be taken when using prucalopride in patients with impaired liver and renal function. In Canada, prucalopride has been approved for treatment of female patients with chronic idiopathic constipation who have failed therapy with at least two laxatives from different classes over a six-month period. No abstract available